Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 in Advanced Solid Tumors
NCT02699515Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2016
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of bintrafusp alfa in solid tumor, sponsored by Merck KGaA. Primary endpoints: Number of Participants With Dose Limiting Toxicity, Number of Participants With Treatment-Emergent Adverse Events and 1 more. Started Mar 2016; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02699515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02699515.